聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响

Effect of Polyethylene Glycol Interferon,PEG-IFN Combined with Entecavir on Liver Function and Liver Fibrosis in Patients with Chronic Hepatitis B

目的探讨聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响。方法选择我院2019年1月-2020年1月收治的98例慢性乙型肝炎患者作为研究对象,按照随机数字表法分为观察组(n=49)和对照组(n=49)。对照组采用恩替卡韦治疗,观察组在此基础上联合聚乙二醇干扰素治疗,比较两组临床疗效、肝功能、肝纤维化及不良反应发生情况。结果观察组总有效率为87.76%,高于对照组的65.31%,差异有统计学意义(P<0.05);治疗后,两组AST、ALT、TBIL、GCT水平及HA、PCⅢ、LN、Ⅳ-C水平均降低,且观察组于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论聚乙二醇干扰素联合恩替卡韦治疗慢性乙型肝炎临床疗效显著,可有效发挥抗病毒作用,改善患者肝功能状态,延缓肝纤维化进程,安全性良好。

Objective To investigate the effect of Polyethylene Glycol Interferon,PEG-IFN combined with entecavir on liver function and liver fibrosis in patients with chronic hepatitis B.Methods A total of 98 patients with chronic hepatitis B admitted to our hospital from January 2019 to January 2020 were selected as the research objects,and were divided into observation group(n=49)and control group(n=49)according to the random number table method.The control group was treated with Entecavir,on this basis,the observation group was combined with Polyethylene Glycol Interferon,PEG-IFN therapy to compare the clinical efficacy of the two groups,liver function,liver fibrosis and adverse reactions.Results The total effective rate of the observation group was 87.76%,which was higher than 65.31%of the control group,the difference was statistically significant(P<0.05);After treatment,the two groups of AST,ALT,TBIL,GCT levels and HA,PCⅢ,LN,IV-C levels decreased,and the observation group was compared with the control group,the difference was statistically significant(P<0.05);There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of Polyethylene Glycol Interferon,PEG-IFN and entecavir has a significant clinical effect in the treatment of chronic hepatitis B.It can effectively exert antiviral effects,improve the liver function status of patients,delay the process of liver fibrosis,and has good safety.